Economic Evaluation of Agomelatine for Major Depressive Disorders Relative to other Antidepressants in the Italian Setting von Lanati, E.P, Lidonnici, D

Volltext

How the Pricing Strategy of 2nd Generation HCV Direct Antiviral Agents Can Affect the Number of Treated Patients in Italy and the National Drug Budget von Lanati, E.P, Lidonnici, D, Cammà, C

Volltext

RWD72 Status of the Art on Global Clinical Trials of Patient-Managed Digital Medical Devices (pDMD): 2023 Original Data Analysis From Multiple Sources von Pagella, V., Lidonnici, D., Lanati, E.P., Rocco, P., Minghetti, P.

Volltext

HPR29 Evolution of the Utilization of the Aifa 5% Fund for Orphan Drugs and Rare Diseases von Tartarelli, F., Viola, V., Lidonnici, D., Marcellusi, A.

Volltext

Cohort Of Hcv Patients In Italy: Sizing And Treatments In A Sample Of Italian Hepatology Centers von Lanati, E.P, Lidonnici, D, Gasbarrini, A, Ruggeri, M, Sacchini, D, Caporaso, N, Fagiuoli, S

Volltext

Patients Diagnostic Therapeutic Pathways For Hcv Patients In Italy: Impact Of Regionalization In Treatments And Guidelines von Lanati, E.P, Lidonnici, D, Gasbarrini, A, Ruggeri, M, Sacchini, D, Caporaso, N, Fagiuoli, S

Volltext

HPR65 Prevalence as a Driver of Treatment Cost for Drugs in the Rare Disease Field in Italy von Casilli, G, Ravasio, R, Lidonnici, D, De Nigris, M

Volltext

HPR158 Progression Free Survival and Duration of Treatment as a Proxy of Disease Severity: Use of These Variables to Determine Price Benchmarks von Mangia, PP, Guardigni, M, Lidonnici, D, Luccini, F

Volltext

HPR160 Analysis of the Time Spent by AIFA Committees for the Assessment of New Drugs: Impact of the Application of Managed Entry Agreements von Brambilla, P, Torriani, A, Lidonnici, D, Ravasio, R, Raimondo, P

Volltext

HPR68 Retrospective Analysis of the Negotiation in AIFA for New Therapeutic Indications von Rossini, E, Lidonnici, D, Casilli, G, Lucchetti, C, Luccini, F

Volltext

PMU48 P&R PROCESS IN ITALY: A FOCUS ON NEGOTIATION OUTCOMES OF INNOVATIVE DRUGS von Enrici, A., Lidonnici, D., Lanati, E.

Volltext

PMU49 NEGOTIATION OUTCOMES IN ITALY: WHAT’S THE IMPACT OF ORPHAN DRUG DESIGNATION? von Enrici, A., Lidonnici, D., Lanati, E.

Volltext

PMH36 - Economic Evaluation of Agomelatine for Major Depressive Disorders Relative to other Antidepressants in the Italian Setting von Lanati, E.P., Lidonnici, D.

Volltext

PRM24 Scan: An Integrated System for Market Access of New Drugs in Italy von Lanati, E.P, Lidonnici, D, D'Ausilio, A, Iorio, A, Jommi, C

Volltext

PMU45 PREVALENCE VS. TREATMENT COST: ANALYSIS OF DRUGS FOR RARE DISEASE IN ITALY von Casilli, G., Lidonnici, D., Morichi, M., Isernia, M., Lanati, E.

Volltext

PMU46 POSITIVE IMPACT OF INNOVATIVE STATUS IN P&R PROCESS TIMING IN ITALY von Enrici, A., Lidonnici, D., Isernia, M., Lanati, E.

Volltext

PMU44 FIFTY SHADES OF... INNOVATIVENESS IN ITALY von Casilli, G., Ronco, V., Lidonnici, D., Lanati, E.

Volltext

PMU47 ORPHAN DRUG DESIGNATION: NO IMPACT ON P&R PROCESS TIMING IN ITALY von Enrici, A., Lidonnici, D., Isernia, M., Lanati, E.

Volltext

PHP76 - ANALYSIS OF APPROVAL TIMING FOR 89 NEW DRUGS IN ITALY FROM JANUARY 2015 TO MAY 2018 von Lidonnici, D., Lanati, E.P., Niedecker, S., Isernia, M.

Volltext

AC1 - OUTCOME OF NEW DRUG NEGOTIATION PROCESS IN ITALY: APPROVAL CONDITIONS (2015-2018) von Lidonnici, D., Lanati, E.P., Niedecker, S., Isernia, M., Ronco, V.

Volltext